



LEAP

LEISHMANIASIS
EAST AFRICA PLATFORM

PROGRAMME

2ND LEISHMANIASIS EAST AFRICA PLATFORM SCIENTIFIC CONFERENCE

Theme: Scientific Innovation and Access for Leishmaniasis Management

**2 - 4 November, 2021,
NAIROBI, KENYA**

This project is part of the EDCTP2 programme
supported by the European Union



EDCTP



DNDi

Drugs for Neglected Diseases *initiative*

2nd LEAP Scientific Conference

Theme: Scientific Innovation and Access for Leishmaniasis Management

CONFERENCE PROGRAMME

2-4 November 2021 – Virtual Meeting (Eastern Africa Time)
Nairobi, Kenya

Tuesday, 2 November 2021 - Programme

Opening Session

12:30 – 13:35 (EAT)	Moderator	Dr Sultani Matendechero, Chairperson of the LEAP Advisory Committee (LAC) Ministry of Health, <i>Kenya</i>
	Welcome and Introduction	Dr Monique Wasunna, DNDi, <i>Kenya</i>
		Prof Muntaser Ibrahim, University of Khartoum, <i>Sudan</i>
		Prof. Samuel Kariuki, Kenya Medical Research Institute, <i>Kenya</i>
		Rolland Kaya, Médecins Sans Frontières Eastern Africa, <i>Kenya</i>
		Dr Juliet Nabyonga-Orem World Health Organization, <i>Kenya</i>
	Dr Bernard Pécoul, DNDi, <i>Switzerland</i>	
	Keynote Speaker	Dr Margaret Anyetei- Agama, African Union, <i>Ethiopia</i>

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Drugs for Neglected Diseases initiative

Session 1 - Leishmaniasis Prevention, Epidemiology, Vector Control and Elimination

13:35-16:00 (EAT)		Chair:	Dr Alfred Mubangizi, Ministry of Health, Uganda
		Co-Chair:	Dr Mousab S. Elhag, Federal Ministry of Health, Sudan
	13:45-14:00	Towards Elimination of Visceral Leishmaniasis in Eastern Africa	Dr Daniel Argaw World Health Organization, Switzerland
	14:00-14:15	Unmet needs in the knowledge of Vector Control in Eastern Africa	Prof Dia El Naiem, University of Maryland, USA
	14:15-14:30	Structuring the political agenda for Leishmaniasis in Eastern Africa	Dr Abate Mulugeta, Regional Office for Africa - World Health Organization, Republic of Congo
	14:30-14:45	Prospects of visceral leishmaniasis elimination in Eastern Africa: applicable lessons drawn from Southeast Asia elimination initiative	Dr Saurabh Jain WHO-TDR, Switzerland
	14:45-15:00	A concerted endeavour for elimination of kala-azar in Eastern Africa for 2030	Dr Carol Karutu, The END Fund, Kenya
	15:00-15:15	The Global Vector Hub - building entomological capacity worldwide and improving epidemic preparedness	Dr Frederik Seelig, London School of Hygiene & Tropical Medicine, United Kingdom
	15:15-15:30	Discussion / Q&A	
	15:30-16:00	Poster Presentations	

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Wednesday, 3 November 2021 - Programme

Session 2 - Advances in R&D and access, diagnosis, and Treatment for Leishmaniasis

12:30- 14:00 (EAT)		Chair: Co-Chair:	Dr Jane Mbuyi , Kenya Medical Research Institute (KEMRI), Kenya Dr Yaw Asare Aboagye , DNDi, Kenya
	12:40-12:55	Phase III PM/MF clinical trial – a more user-friendly option for children with VL	Alexandra Solomos , DNDi, Switzerland
	12:55-13:10	Opportunities in diagnostics and test of cure for VL in Eastern Africa	Dr Henk Schallig , Amsterdam UMC The Netherlands
	13:10-13:20	Investigation of the interactions of some anti-leishmanial natural compounds with potential protein targets: an in-silico approach	Abigail Adomako , Kwame Nkrumah University of Science and Technology, Ghana
	13:20-13:30	Capparis spinosa inhibits Leishmania major promastigote and amastigote growth through induction of Nitric Oxide production	Dounia DARIF , Hassan II University of Casablanca, Morocco
	13:30-13:40	Financial & Administrative Challenges in Clinical Trials Implementation in Resource Limited Settings: Experiences from DNDi sponsored clinical trials in eastern Africa	Simon Bolo , DNDi, Kenya
	13:40-13:55	Progress made on the VL Data Platform, and plans.	Dr Prabin Dahal , Infectious Diseases Data Observatory (IDDO), University of Oxford, UK
	13:55-14:15	Discussion	

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Drugs for Neglected Diseases initiative

Session 3 - Current Advances in Cutaneous Leishmaniasis

14:15-16:05 (EAT)		Chair:	Prof Asrat Hailu , Addis Ababa University, Ethiopia
		Co-Chair:	Dr Esther Kinyeru , Gilgil Hospital, Kenya
	14:25-14:40	CL in Africa	Prof Mourad Mokni , University Tunis Al Manar, Tunisia
	14:40-14:55	Epidemiological situation of CL in Ethiopia	Dr Endalamaw Gadisa , Armauer Hansen Research Institute, Ethiopia
	14:55-15:10	CL: Asian perspective and effects on quality of Life	Prof Nadira Karunaweera , University of Colombo, Sri Lanka
	15:10-15:25	DNDi Efforts on CL	Dr Byron Arana , DNDi, Switzerland
	15:25-15:35	Q&A	
15:35-16:05	Poster Presentations		

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Drugs for Neglected Diseases *initiative*

Thursday, 4 November 2021 - Programme

Session 4 - Leishmaniasis: Basic Science, Translational Research and AVaccine Development

12:30 -13:30 (EAT)		Chair:	Prof Eltahir Khalil Gasim , Institute of Endemic Diseases, University of Khartoum, Sudan
		Co-Chair:	Prof Paul Kaye , University of York, UK
	12:40-12:55	Immunological determinants of chronic visceral leishmaniasis in HIV-coinfected patients	Nicky de Vrij , Institute of Tropical Medicine Antwerp, Belgium
	12:55-13:20	Immunology of <i>L. infantum</i> and <i>L. major</i> infections	Dr Thourya Boussoffara , Institut Pasteur, Tunisia
	13:20-13:35	Immunology of PKDL and CL in SouthEast Asia	Prof Mitali Chatterjee , Post Graduate Institute of Medical Education & Research (PGIMER), India
	13:35-13:50	Development of a centrin-based vaccine for VL	Dr Angamuthu Selvapandiyan , Jamia Hamdard University, India
	13:50-14:00	Q&A	

This project is part of the EDCTP2 programme
supported by the European Union



EDCTP



Drugs for Neglected Diseases initiative

Session 5 - Special Session on the Impact of COVID-19 on NTDs and Training on Fundraising Tools in Africa

14:00-16:30 (EAT)		Chair:	Prof Yalemtehay Mekonnen Addis Ababa University, Ethiopia
		Co-Chair:	Dr Irene Mukui , DNDi, Kenya
	14:10-15:10	Training: Key tools to raise funds for projects and organizations in Africa	Karin Genevoux , Genoka services, France
	15:10-15:20	Q&A	
	15:20-15:35	Effects of COVID-19 on visceral leishmaniasis activities in Uganda	Prof Joseph Olobo , Makerere University, Uganda
	15:35-16:15	Q&A: Open discussion on COVID-19 in Africa: Where are we, Lessons Learnt and What More Needs to be Done	
	15:35-15:55	COVID-19 in Africa: Where are we, Lessons Learnt and What More Needs to be Done	Dr Mohammed Abdulaziz , Africa CDC, Ethiopia
15:55-16:15	Q&A: Open discussion on COVID-19 in Africa		

Session 6: Closing Session

16:15-16:30	Worldleish7 Update	Prof Ivan D. Velez , Universidad de Antioquia, Colombia
	Wrap up and Close of Conference	Dr Jorge Alvar , DNDi, Switzerland

Poster Presentations

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Drugs for Neglected Diseases initiative

Tuesday, November 2, 2021	Leishmaniasis infection among the migrant population of Europe: a systematic review	Dr Melanie Etti , St. George's University of London, UK
	Epidemiology of Visceral Leishmaniasis in Kenya, June-December 2020	Dr Paul Kibati , Ministry of Health, Kenya
	The utility of the Loop-Mediated Isothermal Amplification Assay for Monitoring Anti-leishmanial Treatment Efficacy in visceral leishmaniasis	Dawit Gebreegzabher Hagos , Mekelle University, Ethiopia
	The Translational Prospective of secretory proteins of Mycobacterium tuberculosis encapsulated in Bio-polymeric nanoparticles: An Interplay of Immune Response	Dr Ramendra Pati Pandey , SRM University, India
	Development of a Tropically Stable, Novel Oral Formulation of Amphotericin B to Treat Visceral Leishmaniasis	Dr. Kishor M. Wasan , University of British Columbia, Canada
Wednesday, November 3, 2021	Building capacity for Immunological Research and flow cytometry expertise in Uganda	Alice Bayiyana , Makerere University, Uganda
	Multiplexed qPCR panels to differentiate clinically relevant Leishmania species utilising bisulphite conversion technology	Ineka Gow , University of Technology Sydney, Australia
	Analysis of changes in mitochondrial membrane potential after Photodynamic Therapy in Leishmania promastigotes	Luciana Maria Cortez Marcolino , University of Vale of Paraiba, Brazil
	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin	Aschalew Tamiru , University of Gondar Leishmaniasis Research and Treatment Center, Ethiopia
	Loop-Mediated Isothermal Amplification Assay for the Diagnosis of Leishmaniasis	Dawit Gebreegzabher Hagos , Mekelle University College of Health Sciences, Ethiopia
Soluble adenylate cyclase of Leishmania donovani (LdHemAC) induced cyclic AMP upregulates Nrf2 mediated Heme oxygenase-1 expression promotes its intra-macrophages survival against oxidative stress	Manjay Kumar , ICMR-RM-RIMS, India	

This project is part of the EDCTP2 programme supported by the European Union



EDCTP



Drugs for Neglected Diseases initiative